NCT06914050View on ClinicalTrials.gov

Hypofractionated Radiotherapy Followed by Chemo-immunotherapy Induction Therapy

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2028

Conditions
Lung Cancer, Small CellLimited-stage Small Cell Lung Cancer (LS-SCLC)
Interventions
DRUG

Adebrelimab

Induction therapy：Adebrelimab, 1200mg, d1, q3w, 2 cycles; Maintenance therapy：Adebrelimab, 1200mg, d1, q3w, until disease progression or unbearable toxicity.

DRUG

EC/EP

Chemotherapy: standard chemotherapy EC/EP

RADIATION

SBRT

8Gy\*3

RADIATION

Chest radiotherapy

Chest radiotherapy: conventional fractionation mode 2Gy QD total dose 60Gy or 1.5Gy BID total dose 45Gy, according to the patient's physical condition, concurrent EP or EC chemotherapy can be considered

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER